TLR9 and neoplasm: Lately, TLR-9 agonists have drawn considerable attention at the frontier of research in melanoma immunotherapy since it alters the tumor microenvironment and enhances the anti-tumor immune response by elevating the expression of the TRL-9 receptor [110].